| __timestamp | Pharming Group N.V. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4042025 | 49315000 |
| Thursday, January 1, 2015 | 5279557 | 75043000 |
| Friday, January 1, 2016 | 8073913 | 83749000 |
| Sunday, January 1, 2017 | 44864073 | 122682000 |
| Monday, January 1, 2018 | 53488904 | 207761000 |
| Tuesday, January 1, 2019 | 65896361 | 284812000 |
| Wednesday, January 1, 2020 | 69968267 | 317875000 |
| Friday, January 1, 2021 | 92047281 | 282660000 |
| Saturday, January 1, 2022 | 131819000 | 451421000 |
| Sunday, January 1, 2023 | 87501000 | 481871000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Sarepta Therapeutics, Inc. and Pharming Group N.V., from 2014 to 2023. Over this period, Sarepta Therapeutics consistently outpaced Pharming Group in SG&A spending, reflecting its aggressive growth strategy. By 2023, Sarepta's SG&A expenses had surged by nearly 900%, reaching approximately 482 million, while Pharming's expenses grew by about 2,000%, peaking at around 132 million. This stark contrast highlights Sarepta's larger scale and broader market reach. The data underscores the importance of strategic financial management in the biotech sector, where high SG&A costs can be both a sign of growth and a potential risk. As these companies continue to innovate, their financial strategies will be key to sustaining their competitive edge.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Sarepta Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Pharming Group N.V.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Biogen Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
Genmab A/S and Pharming Group N.V.: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Pharming Group N.V. vs Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Amneal Pharmaceuticals, Inc.